🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exciting afternoon at the #AIforOncology Congress! Inspiring lectures on #LLMs in oncology, AI-driven #DrugDiscovery, and the future of #DigitalTwins in patient care. 🚀 Grateful to be part of a community pushing boundaries for better cancer outcomes! #OncologyAI #Innovation

Emerging Role of Targeted Therapies Combined with Radiotherapy in Inoperable Stage I-III, Non-Small Cell Lung Cancer (NSCLC): A Review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.

APOLLO11: AI-Based Prediction of Long-Term Survival in Patients with NSCLC Treated with IO | OncologyPRO oncologypro.esmo.org/video-series/a…

The 1st edition of an international lung academy with a stellar faculty (clinicians and methodologists). Unmissable opportunity for early and mid-career investigators. Here how to apply forms.gle/etUvYaarjZNV2x… Mihaela Aldea Biagio Ricciuti, MD PhD Università Vita-Salute San Raffaele Gustave Roussy Dana-Farber

Why am I advocating for lung cancer when antisemitism is a more immediate and significant threat to my family’s safety, our lives, and the very existence of my people? It’s always been personal, but the murder of Yaron Lischinsky and Sarah Milgrim hits close to home. Two of my

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer | Cancer Biomarkers | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

So clear that there are T2N1 doing very bad and N3 cured …I am sure we will have genetic profile and ctDNA testing to guide us soon

More data against concurrent IO and XRT Journal of Clinical Oncology. Phase II study of concurrent pembrolizumab + chemoradiation for H&N SCC versus sequential CRT followed by pembro. Sequential had superior PFS and fewer immunosuppressive changes on serial biopsy. ascopubs.org/doi/10.1200/JC…

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

Why is CM816 so important? After Patrick Forde beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…

We have proposed something similar, replacing the PTV with an adaptive target volume (ATV). The ATV is a combination of contour uncertainty under adaptive conditions plus an adjustment for residual intra-fractional motion. Personally, I favor an adaptive target volume, because

Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival. Read the opinion by Alfredo Addeo MD in the #ESMODailyReporter 🔗 ow.ly/Qp9N50W8j2m #SCLC #LungCancer

Please check out our prospective, randomized trial just out in The Lancet Respiratory Medicine 🫁 Stage IA-IIA, non-squamous, surgically resected NSCLC 🧬 Molecular testing of resected tumor 💉 High-risk pts randomized 📉 Adjuvant chemo had DFS benefit vs observation authors.elsevier.com/sd/article/S22…

📢Excited to announce the election of Benjamin Besse as EORTC President-Elect, starting in June 2026, following WinetteVanDerGraaf 🙌 Also, we welcome the new chairs of the Scientific Chairs Council: Anne-Marie Dingemans and Jean-Pascal Machiels!🔬🎉 👉 eortc.org/blog/2025/06/2…

A link to download the Editorial of the Year is now available. QuadShot News sciencedirect.com/science/articl…

Andrea R. Filippi Isabelle Opitz Brendon Stiles Drew Moghanaki QuadShot News Jonathan Spicer MD PhD Heather Wakelee Cecilia Pompili MD PhD FACS There are now several trials of chemo IO prior to surgery or radiation presented or published, including this one from Yilong Wu group cell.com/cancer-cell/fu…